Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImCyse S.A.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.
The US giant is taking a stake in Imcyse and taking over a program to develop RA drugs in a deal that validates the Belgian group's imotope technology.
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
- Large Molecule
Drug Discovery Tools